Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential to reduce treatment costs.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Case Study: Cystic Fibrosis in Adults
Recurrent Pneumonia as a Manifestation of Cystic Fibrosis
- Long COVID/Fatigue Clinic
An Innovative Approach: Neuroplasticity and Predictive Processing
- T-cell lymphomas
Diagnostic Challenges and New Treatment Options
- Interbrain Synchrony
Two Brains, One Thought
- Atopic Dermatitis in Children and Adults
Topically Applied “Small Molecules”: Janus Kinases or PDE-4 as Targets?
- Dermatomyositis
Glucocorticoids for more than one year
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Diabetic Polyneuropathy